The specter of generic competition has repeatedly loomed above copyright’s blockbuster drug, Sildenafil, raising questions about the prospects of connected drug investments. While first years saw substantial gains, the exclusivity end has created the door for cheaper substitutes, potentially reducing revenue and creating a real danger for stakeho